Leader for Translational Research Group
Having gained a PhD in Biochemistry in 2001 from the University of Kent, Fiona joined Imperial College London as a postdoc working with Prof. Dan Davis studying the spatiotemporal localization of proteins at the human Natural Killer immune synapse to determine functional outcomes of NK cell surveillance. She then joined Dr. Richard Williams' lab at the Kennedy Institute in 2006 to study translational immunology using experimental models of rheumatoid arthritis. Specifically, she was the first to identify novel immunoregulatory functions of TNFR2 expressing regulatory T cells in murine arthritis. In 2012, she was appointed to the role of project leader for the Novo Nordisk-KIR clinical research satellite, working on target validation and mechanism of action studies in rheumatoid arthritis. Since March 2015, she has been group leader for the ULTRA-DD consortium (IMI funded research initiative) at the KIR in collaboration with the Structural Genomics Consortium, which aims to study epigenetic modifications in both Dupuytren's disease (with Prof. Jagdeep Nanchahal) and Spondyloarthritis patients (with Prof. Paul Bowness).
Fang H. et al, (2019), Nature Genetics
Tseng W-Y. et al, (2018), ANNALS OF THE RHEUMATIC DISEASES, 77, 250 - 251
Anti-Tumour Necrosis Factor therapy for Dupuytren’s disease: a randomised dose response proof of concept phase 2a clinical trial
Nanchahal J. et al, (2018), EBioMedicine
Moustakim M. et al, (2018), 610, 27 - 58
Tseng WY. et al, (2018), Cytokine, 101, 19 - 25